Navigation Links
Hadasit Bio-Holdings Interviewed by Wall Street Reporter
Date:7/12/2012

JERUSALEM, July 12, 2012 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (OTC: HADSY, TASE: HDST) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced its CEO, Ophir Shahaf, was interviewed by the Wall Street Reporter. The interview discusses key trends in the biotech industry, recent portfolio updates, future business strategy and more.

To listen to the interview click here, http://bit.ly/Mn5zRD, or access the interview directly from the Wall Street Reporter website.

About Hadasit Bio Holdings

Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. Its portfolio companies develop drugs with blockbuster potential (with markets worth over one billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.

For more information please visit: www.hbl.co.il

Investor Contact:
KCSA Strategic Communications
Rob Fink / Josh Dver
212.896.1206 / 1239
rfink@kcsa.com / jdver@kcsa.com


'/>"/>
SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
2. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2018)... ... August 28, 2018 , ... Nanovis , an innovative ... completion of a $5.5 million funding round managed by Commenda Securities. Key investors ... and Ellipsis Ventures. , “Our investment in Nanovis is consistent with our mission ...
(Date:8/29/2018)... ... August 28, 2018 , ... LabRoots , the ... the world, is proud to announce the launch of a new gamification feature, allowing ... chance to win one of LabRoots most popular shirts. , Throughout each month, LabRoots ...
(Date:8/23/2018)... (PRWEB) , ... August 22, 2018 , ... ... ™ for Android on September 1st, making it the first fully-featured app for ... and Android devices. Combined, iOS and Android constitute 99 percent of the market ...
(Date:8/17/2018)... ... , ... The opening of the new Titusville facility marks the completion of ... had a well established local presence, servicing the Space Coast since 1972. Astro Pak ... ongoing work at the Mobile Launch Platform (MLP) in support of NASA’s upcoming Space ...
Breaking Biology Technology:
(Date:9/7/2018)... ... September 05, 2018 , ... ... a mAb manufacturing facility late last year, IPS-Integrated Project Services, LLC and G-CON ... of autologous cell therapies. The iCON solution provides a pre-fabricated modular cleanroom infrastructure ...
(Date:9/7/2018)... DALLAS (PRWEB) , ... September 06, 2018 , ... ... with Amedica Corporation (NASDAQ: AMDA) to purchase its commercial spine business, which includes ... advancements directly related to the spine that result from it. The deal will ...
(Date:8/31/2018)... SCOTTSDALE, Ariz. (PRWEB) , ... August 30, 2018 ... ... therapies, is now offering a complimentary cryogenic freezer program for new clients. The ... procedures. , The regenerative biologics from R3 Stem Cell consist of amniotic and ...
Breaking Biology News(10 mins):